{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    62,
    65,
    73,
    74,
    79,
    88,
    89,
    90,
    93,
    94,
    95,
    146,
    113,
    116,
    123
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study drug",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Baseline Visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening period",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_9",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_15",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_daily_94",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "Screening period"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "follow-Up Period"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "P260W",
        "interval": "P1D",
        "minObservations": 1820,
        "exitCondition": "Completion of Period 2 (246 weeks) or failure to show 20% improvement in TJC/SJC at 2 consecutive visits after Week 26",
        "sourceText": "1 tablet once daily (upadacitinib or matching placebo) to maintain blinding."
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P7D",
        "minObservations": 14,
        "exitCondition": "End of Period 1",
        "sourceText": "Each subject will be instructed to take a required number of capsules once weekly (MTX and/or matching placebo)"
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P1D",
        "minObservations": 98,
        "exitCondition": "End of Period 1",
        "sourceText": "all subjects should take a dietary supplement of folic acid (or equivalent) throughout Period 1 participation"
      },
      {
        "id": "rep_llm_4",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P14W",
        "minObservations": 1,
        "exitCondition": "Completion of Week 14 visit",
        "sourceText": "a 14-week randomized, double-blind, parallel-group, controlled treatment period (Period 1)"
      },
      {
        "id": "rep_llm_5",
        "type": "Cycle",
        "startOffset": "P14W",
        "endOffset": "P260W",
        "interval": "P246W",
        "minObservations": 1,
        "exitCondition": "Completion of 246 weeks",
        "sourceText": "a 246-week blinded extension period (Period 2)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "Period 1 and Period 2"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "PERIOD_1_TREATMENT",
          "PERIOD_2_LONG_TERM_EXTENSION",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Week 14",
          "Baseline",
          "Screening",
          "Day 1",
          "End of Study",
          "Safety Follow-up"
        ],
        "sourceText": "[{'condition': 'Completion of Period 1 (14 weeks)', 'path': ['PERIOD_2_LONG_TERM_EXTENSION']}, {'condition': 'Gastrointestinal perforation (excluding appendicitis/mechanical injury)', 'path': ['IMMEDIATE_DISCONTINUATION']}, {'condition': 'Confirmed ALT or AST > 8 x ULN', 'path': ['STUDY_DRUG_INTERRUPTION', 'MEDICAL_DIRECTOR_CONSULTATION']}, {'condition': 'State of emergency or pandemic (e.g., COVID-19)', 'path': ['HOME_HEALTHCARE_SERVICE', 'LOCAL_LAB_TESTING', 'DIRECT_TO_PATIENT_SHIPMENT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Sign",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 3"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "X-Ray",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 4"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3; SINGLE signals: 3"
      },
      {
        "activityId": "Patient's Assessment of Severity and Duration of Morning Stiffness Numerical Rating Scale",
        "executionType": "Single",
        "rationale": "The protocol specifies this questionnaire is collected at scheduled intervals until Week 276, indicating a recurring assessment at study visits."
      },
      {
        "activityId": "Chest X-rays (CXR)",
        "executionType": "Single",
        "rationale": "The protocol describes these as specific assessments (e.g., annual or at screening) rather than continuous monitoring."
      },
      {
        "activityId": "TB Testing/TB Prophylaxis",
        "executionType": "Single",
        "rationale": "The protocol describes a conditional workflow where CXRs or prophylaxis are triggered by specific decision points, such as seroconversion on an annual TB test."
      },
      {
        "activityId": "Outcomes and Questionnaires (Pandemic/Emergency Protocol)",
        "executionType": "Single",
        "rationale": "The protocol outlines a conditional workflow where if an onsite visit cannot be performed due to a pandemic, the activity is deferred to the next feasible visit."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "Period 1 and Period 2"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. If a subject prematurely discontinues study participation, the procedures outlined for the Premature Discontinuation visit (PD visit) should be completed as soon as possible.",
        "footnoteId": "fn_1",
        "structuredCondition": "event.premature_discontinuation == true",
        "appliesToActivityIds": [
          "Premature Discontinuation visit procedures"
        ],
        "sourceText": "a. If a subject prematurely discontinues study participation, the procedures outlined for the Premat"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. The Baseline visit procedures will serve as the reference for all subsequent visits with the exception of the ECG.",
        "footnoteId": "fn_2",
        "structuredCondition": "reference_point == Baseline && activity != ECG",
        "appliesToActivityIds": [
          "All subsequent visit procedures"
        ],
        "sourceText": "b. The Baseline visit procedures will serve as the reference for all subsequent visits with the exce"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. This visit is 30 days after last dose of study drug for those subjects who complete Period 1 and do not enter Period 2.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.after(last_dose, P30D) && subject.period_2_entry == false",
        "appliesToActivityIds": [
          "Follow-up visit"
        ],
        "sourceText": "c. This visit is 30 days after last dose of study drug for those subjects who complete Period 1 and "
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "l. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.before(blood_draws)",
        "appliesToActivityIds": [
          "Blood pressure",
          "Pulse rate",
          "Body temperature",
          "Respiratory rate"
        ],
        "sourceText": "l. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blo"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "u. At Week 2 and Week 4 visits, PK samples should be collected prior to dosing.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.before(dosing)",
        "appliesToActivityIds": [
          "PK samples"
        ],
        "sourceText": "u. At Week 2 and Week 4 visits, PK samples should be collected prior to dosing."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "w. Samples only collected if subject provides written consent.",
        "footnoteId": "fn_6",
        "structuredCondition": "subject.written_consent == true",
        "appliesToActivityIds": [
          "Samples"
        ],
        "sourceText": "w. Samples only collected if subject provides written consent."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "x. For subjects entering Period 2.",
        "footnoteId": "fn_7",
        "structuredCondition": "subject.period_2_entry == true",
        "appliesToActivityIds": [
          "Period 2 activities"
        ],
        "sourceText": "x. For subjects entering Period 2."
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: ACR20 Response (US/FDA)",
        "endpointType": "Primary",
        "inputs": [
          "TJC",
          "SJC",
          "Patient Assessment of Pain VAS",
          "Patient Global Assessment of Disease Activity VAS",
          "Physician Global Assessment of Disease Activity VAS",
          "HAQ-DI",
          "hsCRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "14 weeks"
        },
        "algorithm": "(Improvement in TJC >= 20%) AND (Improvement in SJC >= 20%) AND (Improvement in >= 3 of 5 remaining measures >= 20%)",
        "successCriteria": "20% or greater improvement in TJC and SJC and 3 of 5 additional measures",
        "sourceText": "ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual A"
      },
      {
        "id": "ep_2",
        "name": "Primary: Low Disease Activity (EU/EMA)",
        "endpointType": "Primary",
        "inputs": [
          "DAS28",
          "CRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "14 weeks"
        },
        "algorithm": "DAS28(CRP) <= 3.2",
        "successCriteria": "DAS28 (CRP) score less than or equal to 3.2",
        "sourceText": "LDA is defined as Disease Activity Score (DAS) 28 (C-reactive protein [CRP]) ≤ 3.2."
      },
      {
        "id": "ep_3",
        "name": "Secondary: Clinical Remission (CR)",
        "endpointType": "Secondary",
        "inputs": [
          "DAS28",
          "CRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "14 weeks"
        },
        "algorithm": "DAS28(CRP) < 2.6",
        "successCriteria": "DAS28 (CRP) score less than 2.6",
        "sourceText": "CR [based on DAS28 (CRP)] < 2.6"
      },
      {
        "id": "ep_4",
        "name": "Secondary: Change from Baseline in DAS28 (CRP)",
        "endpointType": "Secondary",
        "inputs": [
          "DAS28(CRP)_Baseline",
          "DAS28(CRP)_Week14"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "14 weeks"
        },
        "algorithm": "Week 14 value - Baseline value",
        "successCriteria": "Statistically significant reduction from baseline",
        "sourceText": "Change from baseline in DAS28 (CRP)"
      },
      {
        "id": "ep_5",
        "name": "Secondary: HAQ-DI Response",
        "endpointType": "Secondary",
        "inputs": [
          "HAQ-DI_Baseline",
          "HAQ-DI_Followup"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Variable"
        },
        "algorithm": "(Followup_Value - Baseline_Value) <= -0.22",
        "successCriteria": "Reduction in HAQ-DI of at least 0.22",
        "sourceText": "Proportion of subjects with change from baseline in HAQ-DI ≤ –0.22"
      },
      {
        "id": "ep_6",
        "name": "Secondary: SDAI Low Disease Activity",
        "endpointType": "Secondary",
        "inputs": [
          "SDAI"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Variable"
        },
        "algorithm": "SDAI <= 11.0",
        "successCriteria": "SDAI score less than or equal to 11.0",
        "sourceText": "SDAI LDA ≤ 11.0"
      },
      {
        "id": "ep_7",
        "name": "Secondary: CDAI Clinical Remission",
        "endpointType": "Secondary",
        "inputs": [
          "CDAI"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Variable"
        },
        "algorithm": "CDAI <= 2.8",
        "successCriteria": "CDAI score less than or equal to 2.8",
        "sourceText": "CDAI CR ≤ 2.8"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from baseline in DAS28 (CRP)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "Visit_value - Baseline_value",
        "baselineDefinition": "Last non-missing value before first dose of study drug",
        "baselineVisit": "Baseline Visit",
        "analysisWindow": "Week 14, Week 20, Week 26, Week 36, Week 48, every 12 weeks through Week 240, and Week 260/PD",
        "imputationRule": "Not explicitly stated for all endpoints; unblinded analysis at Week 14 mentioned",
        "unit": "Score"
      },
      {
        "id": "dv_2",
        "name": "Low Disease Activity (LDA) based on DAS28 (CRP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "If DAS28 (CRP) <= 3.2 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable for status at visit",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Week 14 and subsequent visits",
        "imputationRule": "Not explicitly stated",
        "unit": "Boolean"
      },
      {
        "id": "dv_3",
        "name": "Clinical Remission (CR) based on DAS28 (CRP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "If DAS28 (CRP) < 2.6 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Week 14 and subsequent visits",
        "imputationRule": "Not explicitly stated",
        "unit": "Boolean"
      },
      {
        "id": "dv_4",
        "name": "ACR20/50/70 response rate",
        "variableType": "Composite",
        "sourceVariables": [
          "TJC",
          "SJC",
          "Patient Global Assessment",
          "Physician Global Assessment",
          "Pain",
          "HAQ-DI",
          "CRP/ESR"
        ],
        "derivationRule": "At least 20%/50%/70% improvement in both TJC and SJC and at least 20%/50%/70% improvement in 3 of the 5 remaining ACR components",
        "baselineDefinition": "Values at Baseline Visit",
        "baselineVisit": "Baseline Visit",
        "analysisWindow": "Week 14, Week 20, Week 26, Week 36, Week 48, every 12 weeks through Week 240, and Week 260/PD",
        "imputationRule": "Not explicitly stated",
        "unit": "Rate"
      },
      {
        "id": "dv_5",
        "name": "Change from baseline in HAQ-DI",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "HAQ-DI"
        ],
        "derivationRule": "Visit_value - Baseline_value",
        "baselineDefinition": "Last non-missing value before first dose of study drug",
        "baselineVisit": "Baseline Visit",
        "analysisWindow": "Week 14",
        "imputationRule": "Not explicitly stated",
        "unit": "Score"
      },
      {
        "id": "dv_6",
        "name": "HAQ-DI Response (MCID)",
        "variableType": "Categorical",
        "sourceVariables": [
          "HAQ-DI"
        ],
        "derivationRule": "If (Visit_value - Baseline_value) <= -0.22 then 'Yes' else 'No'",
        "baselineDefinition": "Last non-missing value before first dose of study drug",
        "baselineVisit": "Baseline Visit",
        "analysisWindow": "Week 14",
        "imputationRule": "Not explicitly stated",
        "unit": "Boolean"
      },
      {
        "id": "dv_7",
        "name": "Percent improvement in TJC and SJC",
        "variableType": "PercentChange",
        "sourceVariables": [
          "TJC",
          "SJC"
        ],
        "derivationRule": "((Visit_value - Baseline_value) / Baseline_value) * 100",
        "baselineDefinition": "Values at Baseline Visit",
        "baselineVisit": "Baseline Visit",
        "analysisWindow": "Starting at Week 26 and thereafter (for rescue/discontinuation criteria)",
        "imputationRule": "Not explicitly stated",
        "unit": "%"
      },
      {
        "id": "dv_8",
        "name": "Low Disease Activity (LDA) based on CDAI",
        "variableType": "Categorical",
        "sourceVariables": [
          "CDAI"
        ],
        "derivationRule": "If CDAI <= 10 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Week 26 (for rescue medication adjustment)",
        "imputationRule": "Not explicitly stated",
        "unit": "Boolean"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Period 1 Treatment",
        "Period 2 Long Term Extension",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Period 1 Treatment",
          "trigger": "Progress to Period 1 Treatment"
        },
        {
          "fromState": "Period 1 Treatment",
          "toState": "Period 2 Long Term Extension",
          "trigger": "Progress to Period 2 Long Term Extension"
        },
        {
          "fromState": "Period 2 Long Term Extension",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Period 1 Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Period 2 Long Term Extension",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Period 1 Treatment": "PERIOD_1_TREATMENT",
        "Period 2 Long Term Extension": "PERIOD_2_LONG_TERM_EXTENSION",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Upadacitinib",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "At least 276 weeks",
        "doseModifications": [
          "Discontinue study drug treatment immediately if subject develops a gastrointestinal perforation (except appendicitis or mechanical injury)",
          "Immediate study drug interruption for confirmed ALT or AST > 8 × ULN",
          "Provisions for study drug interruptions due to COVID-19"
        ],
        "sourceText": "246-week blinded extension period (Period 2); and a 30-day follow-up visit. Subjects who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:  Group 1: Upa"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 35,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening. Subjects must have been on oral or parenteral M"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Specified that questionnaires are not eligible for completion by virtual interview in the event that an onsite visit cannot be performed due to a pandemic or state of emergency and will be completed a"
      },
      {
        "id": "visit_6",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Period 1",
        "sourceText": "will start on their blinded upadacitinib (30 mg QD, 15 mg QD or Placebo QD) dose at Baseline. Also, starting at Baseline, all subjects will discontinue their current MTX treatment and start their blin"
      },
      {
        "id": "visit_13",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "medications through the end of study drug administration: ● Humira® (adalimumab)"
      },
      {
        "id": "visit_5",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "≥12.5 mg/week] for at least 4 weeks. No MTX washout is needed prior to randomization. All subjects will start on their blinded upadacitinib (30 mg QD, 15 mg QD or Placebo QD) dose at Baseline. Also, s"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Follow-up Visit",
        "targetDay": 30,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_11",
        "visitName": "Week 12",
        "targetDay": 78,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 12,
        "sourceText": "greatest unmet need, the primary endpoint of ACR20 response rate at Week 12 was significantly greater at all doses of upadacitinib (up to 73%) compared with placebo (35%). In addition, numerically hig"
      },
      {
        "id": "visit_8",
        "visitName": "Week 14",
        "targetDay": 92,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 14,
        "epoch": "Period 1",
        "sourceText": "Subjects who complete the Week 14 visit (end of Period 1) will enter the blinded long-term extension portion of the study, Period 2 (246 weeks). Subjects who are assigned to upadacitinib treatment gro"
      },
      {
        "id": "visit_7",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 26,
        "epoch": "Period 2",
        "sourceText": "equivalent) throughout Period 1 participation; while in Period 2 (starting at Week 26) it should only be taken if MTX is given as background medication. Folic acid dosing and timing of regimen should "
      },
      {
        "id": "visit_10",
        "visitName": "Week 48",
        "targetDay": 330,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 48,
        "sourceText": "Week 48 only:  Change from baseline in EQ-5D-5L;"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "and a 30-day follow-up visit. Subjects who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:"
      },
      {
        "id": "visit_9",
        "visitName": "Week 240",
        "targetDay": 1674,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 240,
        "sourceText": "Weeks 20, 26, 36, 48, every 12 weeks through Week 240, and Week 260/PD:  ACR20/50/70 response rates;"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Week 260",
        "targetDay": 1821,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 260,
        "epoch": "Period 2"
      },
      {
        "id": "visit_2",
        "visitName": "Week 276",
        "targetDay": 1926,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 276,
        "epoch": "Period 2",
        "sourceText": "not be collected starting at Week 276 for consistency with footnote \"c.\" of Table 4 \"Study Activities (Period 2).\" ○"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:2:1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "geographic region at screening"
        },
        {
          "id": "strat_llm_1",
          "name": "Main stratification factors",
          "categories": "Not explicitly listed in provided text",
          "isBlocking": false
        }
      ],
      "sourceText": "Upadacitinib\nM15-555 Protocol Amendment 7\nEudraCT 2015-003376-75\n10\nMethodology (Continued):\nThe study duration will include a 35-day screening period; a 14-week randomized, double-blind, \nparallel-gr"
    }
  }
}